Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glofitamab plus Gemox for interim non-responders with diffuse large B-cell lymphoma
ChiCTR2400086734Phase 2Not yet recruiting
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Jul 2024
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of glofitamab in diffuse large B-cell lymphoma (DLBCL), sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoint: complete remission rate. Planned start Jul 2024; status: not yet recruiting.
02
Drugs
glofitamab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on ChiCTR2400086734.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400086734.